

Extended anticoagulation tied to major bleeding risk

September 14 2021



(HealthDay)—The long-term risks and consequences of anticoagulant-

related major bleeding are considerable among patients receiving extended oral anticoagulant therapy for a first unprovoked venous thromboembolism (VTE), according to a review published online Sept. 14 in the *Annals of Internal Medicine*.

Faizan Khan, from the University of Ottawa in Canada, and colleagues examined the incidence of major bleeding during extended anticoagulation of up to five years among patients with a first unprovoked VTE in a [systematic review](#) and meta-analysis. Data were included from 14 randomized controlled trials and 13 cohort studies with 9,982 patients who received a vitamin K antagonist (VKA) and 7,220 who received a direct oral anticoagulant (DOAC).

The researchers found that the incidence of major bleeding was 1.74 and 1.12 events per 100 person-years with VKAs and DOACs, respectively. With VKAs, the five-year cumulative incidence of major bleeding was 6.3 percent. The incidence of major bleeding was statistically significantly higher among [patients](#) receiving either VKA or DOAC who were older than 65 years or had creatinine clearance

Citation: Extended anticoagulation tied to major bleeding risk (2021, September 14) retrieved 19 November 2023 from <https://medicalxpress.com/news/2021-09-anticoagulation-tied-major.html>

| |
|--|
| <p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p> |
|--|